SG141358A1 - Treatment of psychiatric patients with reduced heptaic function with paliperidone - Google Patents

Treatment of psychiatric patients with reduced heptaic function with paliperidone

Info

Publication number
SG141358A1
SG141358A1 SG200708352-0A SG2007083520A SG141358A1 SG 141358 A1 SG141358 A1 SG 141358A1 SG 2007083520 A SG2007083520 A SG 2007083520A SG 141358 A1 SG141358 A1 SG 141358A1
Authority
SG
Singapore
Prior art keywords
paliperidone
treatment
psychiatric patients
heptaic
reduced
Prior art date
Application number
SG200708352-0A
Other languages
English (en)
Inventor
Sandra Boom
Marielle-Henriette Erdekens
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SG141358A1 publication Critical patent/SG141358A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG200708352-0A 2006-09-22 2007-09-20 Treatment of psychiatric patients with reduced heptaic function with paliperidone SG141358A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/534,623 US20070197591A1 (en) 2005-12-12 2006-09-22 Use of paliperidone for the treatment of a mental disorder in a psychiatric patient with reduced hepatic function

Publications (1)

Publication Number Publication Date
SG141358A1 true SG141358A1 (en) 2008-04-28

Family

ID=38805865

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200708352-0A SG141358A1 (en) 2006-09-22 2007-09-20 Treatment of psychiatric patients with reduced heptaic function with paliperidone

Country Status (11)

Country Link
US (1) US20070197591A1 (de)
EP (1) EP1902715A3 (de)
JP (1) JP2008074852A (de)
CN (1) CN101264084A (de)
AU (1) AU2007216873A1 (de)
BR (1) BRPI0703970A2 (de)
CO (1) CO6080090A1 (de)
MX (1) MX2007011783A (de)
RU (1) RU2007135202A (de)
SG (1) SG141358A1 (de)
ZA (1) ZA200708158B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US8579814B2 (en) * 2007-01-05 2013-11-12 Idexx Laboratories, Inc. Method and system for representation of current and historical medical data
LT2234617T (lt) * 2007-12-19 2021-05-25 Janssen Pharmaceutica Nv Dozės režimai, susiję su ilgo veikimo injekuojamais paliperidono esteriais
EP2485712A1 (de) * 2009-10-06 2012-08-15 Ascendis Pharma A/S Subkutane paliperidonzusammensetzung
WO2011042450A1 (en) * 2009-10-06 2011-04-14 Ascendis Pharma As Carrier linked paliperidone prodrugs
BR112012010195A2 (pt) * 2009-10-30 2016-04-26 Janssen Pharmaceutica Nv regime de dosagem associado a ésteres de paliperidona injetável de longa ação
US9271939B2 (en) 2010-03-15 2016-03-01 Inventia Healthcare Private Limited Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic
WO2018217766A1 (en) * 2017-05-22 2018-11-29 Whitehead Institute For Biomedical Research Kcc2 expression enhancing compounds and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2000786C (en) 1988-11-07 1999-01-26 Cornelus G. M. Janssen 3-piperidinyl-1,2-benzisoxazoles
WO2000010572A1 (en) * 1998-08-18 2000-03-02 Sepracor Inc. Use of hydroxyrisperidone for the manufacture of a medicament for the treatment and prevention of psychoses, emesis and symptoms of withdrawal from alcohol and nicotine
WO2005063296A2 (en) * 2003-12-23 2005-07-14 Pfizer Products Inc. Therapeutic combination for cognition enhancement and psychotic disorders

Also Published As

Publication number Publication date
RU2007135202A (ru) 2009-03-27
AU2007216873A1 (en) 2008-04-10
EP1902715A2 (de) 2008-03-26
CN101264084A (zh) 2008-09-17
EP1902715A3 (de) 2008-11-12
JP2008074852A (ja) 2008-04-03
BRPI0703970A2 (pt) 2009-05-26
ZA200708158B (en) 2009-08-26
MX2007011783A (es) 2009-02-19
US20070197591A1 (en) 2007-08-23
CO6080090A1 (es) 2009-09-30

Similar Documents

Publication Publication Date Title
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
SG141358A1 (en) Treatment of psychiatric patients with reduced heptaic function with paliperidone
MX2020008616A (es) Rocio de fentanilo sublingual.
WO2007136759A3 (en) Method for the treatment and prevention of ocular disorders
WO2009017837A3 (en) Sublingual fentanyl spray
MX2010013766A (es) Rasagilina para modificacion de enfermedad de parkinson.
SG10201400685SA (en) Use Of Eicosapentaenoic Acid Ethyl Ester For Treating Hypertriglyceridemia
WO2008124085A3 (en) Methods of using combinations of mek and jak-2 inhibitors
NZ593199A (en) Milnacipran for the long-term treatment of fybromyalgia syndrome
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
TN2010000135A1 (en) Galenical formulations of organic compounds
WO2007149283A3 (en) Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload
UA96575C2 (en) Process for the preparation of olmesartan medoxomil
PL2205279T3 (pl) Farmaceutyczna kombinacja aliskirenu i walsartanu
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
WO2011076208A3 (en) Calcipotriol monohydrate nanocrystals
MX366496B (es) Metodos para preparar composiciones farmaceuticas que comprenden acetato de eslicarbazepina y metodos de uso.
WO2010022326A3 (en) Transdermal delivery of apomorphine using microneedles
WO2008063847A3 (en) Method for treating autism
SG10201809506TA (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
WO2007092436A3 (en) Compounds for treating inflammatory disorders, demyelinating disorders and cancers
EP2392335A3 (de) Verwendung von 24-norUDCA
WO2006133231A3 (en) Treatment for neurodegenerative diseases
MY145122A (en) Phenylacetic acid derivatives as cox-2 inhibitors